Companies Sagimet Biosciences Inc.
Sagimet Biosciences (SGMT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Sagimet Biosciences Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,685,917FY2023
- $906,164FY2024
- $3,239,994FY2025
CEO total pay was $3,239,994 in fiscal 2025, up from $906,164 in fiscal 2024.
FY2025: salary $630,000 · bonus $0 · stock awards $546,360 · option awards $1,749,751
Order SGMT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Happel | $630,000 | $0 | $546,360 | $1,749,751 | $294,525 | $0 | $19,358 | $3,239,994 |
| President and Chief Executive Officer | ||||||||
| Elizabeth Rozek | 483,333 | 0 | 235,137 | 591,668 | 170,000 | 0 | 16,564 | 1,496,702 |
| Chief Legal and Administrative Officer | ||||||||
| Eduardo Martins | 500,000 | 0 | 160,140 | 511,580 | 170,000 | 0 | 19,121 | 1,360,841 |
| Former Chief Medical Officer | ||||||||
| Eduardo D.Phil | 500,000 | 0 | 160,140 | 511,580 | 170,000 | 0 | 19,121 | 1,360,841 |
| Former Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Happel | $3,239,994 | $906,164 | $2,685,917 | ↑ +2,333,830 |
| Elizabeth Rozek | 1,496,702 | 626,142 | — | ↑ +870,560 |
| Eduardo Martins | 1,360,841 | — | — | — |
| Eduardo D.Phil | 1,360,841 | 669,064 | 1,509,081 | ↑ +691,777 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company considers compensation for comparable positions in the market, historical compensation levels, individual performance, and the desire to motivate employees to achieve short- and long-term results in the best interests of stockholders. Equity awards are used to create an ownership culture, align interests with stockholders, and promote executive retention through time-based vesting.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | false |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Happel | OPTION | 2025-02-06 | — | — | 472,000 | — | $1,749,751 |
| Elizabeth Rozek | OPTION | 2025-02-06 | — | — | 138,000 | — | — |
| Elizabeth Rozek | OPTION | 2025-11-04 | — | — | 13,367 | — | — |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Happel | $0 | $0 | $1,749,751 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Elizabeth Rozek | RSU | 9,855 | — | $58,342 |
| Elizabeth Rozek | Option | 13,089 | 7.61 | — |
| Eduardo Martins | Option | 14,665 | 13.51 | — |
| Elizabeth Rozek | RSU | 34,000 | — | 201,280 |
| Eduardo Martins | RSU | 34,000 | — | 201,280 |
| Eduardo Martins | RSU | 44,785 | — | 265,127 |
| Elizabeth Rozek | Option | 80,704 | 13.51 | — |
| Elizabeth Rozek | RSU | 85,710 | — | 507,403 |
| Elizabeth Rozek | Option | 109,250 | 4.71 | — |
| Eduardo Martins | Option | 109,250 | 4.71 | — |
| David Happel | RSU | 116,000 | — | 686,720 |
| David Happel | Option | 210,786 | 7.15 | — |
| David Happel | RSU | 312,455 | — | 1,849,734 |
| David Happel | Option | 373,667 | 4.71 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Beth Seidenberg, M.DIndependent · Lead Independent Director · Compensation (Chair) | $66,331 | $129,864 | — | — | $120,083 | $316,278 |
| Paul HoelscherIndependent | 55,000 | 129,864 | — | — | 0 | 184,864 |
| Timothy P. WalbertIndependent | 52,500 | 129,864 | — | — | 0 | 182,364 |
| Elizabeth Grammer, EsqIndependent · Nominating/Governance (Chair) · Partial-year service | 50,000 | 129,864 | — | — | 0 | 179,864 |
| George Kemble, Ph.DIndependent · Partial-year service | 45,726 | 129,864 | — | — | 0 | 175,590 |
| Jennifer JarrettIndependent | 47,500 | 109,803 | — | — | 0 | 157,303 |
| Anne Phillips, M.DIndependent · Compensation · Nominating/Governance | 47,306 | 109,803 | — | — | 0 | 157,109 |
| Merdad Parsey, M.D., Ph.DIndependent · Not standing for re-election · Departed during FY | 21,863 | 0 | — | — | 0 | 21,863 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $386,226 |
| Equity awards (grant-date value) | $868,926 |
| All other compensation | $120,083 |
| Total cost of the board | $1,375,235 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sagimet Biosciences as a peer
Companies that benchmark against SGMT
No companies currently name SGMT as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Sagimet Biosciences Inc. | 2025 | David Happel | $630,000 | $546,360 | $1,749,751 | $294,525 | $3,239,994 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (19 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, David Happel. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 3,239,994. View filing ↗
- Section 01, Elizabeth Rozek. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 1,496,702. View filing ↗
- Section 01, Eduardo Martins. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 1,360,841. View filing ↗
- Section 01, Eduardo D.Phil. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 1,360,841. View filing ↗
- Section 03, David Happel OPTION. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Elizabeth Rozek OPTION. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Elizabeth Rozek OPTION. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Beth Seidenberg, M.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 316,278. View filing ↗
- Section 08, Paul Hoelscher. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 184,864. View filing ↗
- Section 08, Timothy P. Walbert. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 182,364. View filing ↗
- Section 08, Elizabeth Grammer, Esq. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 179,864. View filing ↗
- Section 08, George Kemble, Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 175,590. View filing ↗
- Section 08, Jennifer Jarrett. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 157,303. View filing ↗
- Section 08, Anne Phillips, M.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 157,109. View filing ↗
- Section 08, Merdad Parsey, M.D., Ph.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 21,863. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 386,226 + equity 868,926 + all other 120,083 = 1,375,235, summed across the director compensation table rows.
- Sagimet Biosciences Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Sagimet Biosciences Inc.'s own proxy. As printed: 3,239,994. View filing ↗